Close

toralizumab (TAB-876)

DESCRIPTION CATALOG # SIZE PRICE
Anti-Human CD40 ligand Therapeutic Antibody TAB-876 1mg Please Inquiry

PRODUCT INFORMATION

  • Product Overview
  • Recombinant humanized (from mouse) antibody expressed in CHO binding to human CD40 ligand. Toralizumab was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).
  • Target
  • CD40 ligand
  • Type
  • IgG1 - kappa
  • Immunogen
  • The details of the immunogen for this antibody are not available.
  • Species Reactivity
  • Human
  • Expression Host
  • CHO
  • Applications
  • Suitable for use in ELISA, FC, IP, FuncS, IF, Neut, ICC and most other immunological methods.
  • CAS
  • 252662-47-8
  • Predicted N terminal
  • MIETYNQT
  • Molecular Weight
  • 148.426kDa
  • Purity
  • >95.0% as determined by Analysis by RP-HPLC & analysis by SDS-PAGE.
  • Size
  • 1mg
  • Storage
  • Store at -20°C for long-term storage. Store at 2-8°C for up to one month. Avoid freeze/thaw cycles.

BACKGROUND

  • Introduction
  • Toralizumab was a humanized monoclonal antibody and an immunosuppressive drug. Possible indications included treatment of antibody-mediated disorders (immune thrombocytopenic purpura, lupus nephritis, rheumatoid arthritis), T-cell-mediated diseases (multiple sclerosis, Crohn's disease, and transplantations such as solid organ transplantation, pancreatic islet cell transplantation, and corneal transplantation), and B-cell malignancies such as CLL/small lymphocytic lymphoma, follicular cell lymphoma grade I or II, marginal zone lymphoma, mantle cell lymphoma, MALT lymphoma, Waldenstrom's macroglobulinemia, monocytoid B-cell lymphoma; relapsed/refractory Hodgkin's disease).
  • Antigen Description
  • Mediates B-cell proliferation in the absence of co-stimulus as well as IgE production in the presence of IL-4. Involved in immunoglobulin class switching.
    Release of soluble CD40L from platelets is partially regulated by GP IIb/IIIa, actin polymerization, and an matrix metalloproteinases (MMP) inhibitor-sensitive pathway.
  • Function
  • CD40 receptor binding; cytokine activity; tumor necrosis factor receptor binding;
  • Synonyms
  • CD40LG; CD40 ligand; HIGM1, IMD3, TNFSF5, tumor necrosis factor (ligand) superfamily, member 5 (hyper IgM syndrome); CD40 antigen ligand; CD40L; CD154; gp39; hCD40L; hyper IgM syndrome; T B cell activating molecule; TNF related activation protein; TRAP; tumor necrosis factor (ligand) superfamily member 5; CD40-L; T-cell antigen Gp39; T-B cell-activating molecule; TNF-related activation protein; IGM; IMD3; HIGM1; T-BAM; TNFSF5;

Related Products

Online Inquiry

Verification code
Click image to refresh the verification code.

CONTACT US

45-1 Ramsey Road, Shirley, NY 11967, USA
Call us at:
USA: 1-631-381-2994
Europe: 44-207-097-1828
Fax: 1-631-207-8356
Email:
Our customer service representatives are available 24 hours a day, 7 days a week. Contact Us